ZIOP - MyoKardia's Positive Data And Other News: The Good Bad And Ugly Of Biopharma
MyoKardia Reports Upbeat Phase 2a Clinical Data
MyoKardia Inc. (MYOK) announced that its Phase 2a clinical trial of danicamtiv has yielded positive results. The company also discussed nonclinical data showing the novel mechanism of action of the drug candidate. Danicamtiv is MyoKardia’s lead drug candidate and is being developed for treating conditions mainly caused due to declining systolic function.
Phase 2a study involved the administration of the drug candidate orally for seven days in patients showing stable chronic heart failure. The data showed clinically meaningful improvements in left ventricular contractility, including statistically significant